Bespak plc Addresses India’s Biopharmaceutical Drive For High Value Drug Delivery Products That Differentiate Generics, Biobetters And Biosimilars At CPhI India 2015
The company showcases the innovative Syrina™ 2.25 auto-injector that brings the flexibility to design a unique form factor and also the full Syrina™ platform accommodating multiple primary containers and high viscous, high volume injections
3 Dec 2015: Bespak, the leading, global drug delivery company, is attending CPhI India 2015, and is utilising the internationally sponsored event to meet clients and to further highlight how its technology, in the field of combination products, auto injectors and pen injectors, can best assist the complex requirements of India based biopharmaceutical companies. To date, Bespak has built-up and established strong customer relationships with many of the country’s leading biopharmaceutical companies for a range of products from Metered Dose Inhaler (MDI) valves, injectables, respiratory devices and more.
Steven Kaufman, Bespak’s Global Business Development Lead, commented: “India’s biopharmaceutical sector is on the look-out for highly innovative drug and delivery device solutions that provide a competitive edge for their products. Consequently, we are seeking to use this event to maintain our close relationships with our customers, whilst demonstrating how we can best service their needs with advanced drug delivery device technology that further increases value by helping to differentiate their generic, biobetter and biosimilar drugs.”
He continued: “For example, we will be demonstrating how our latest addition to the Syrina™ product range, the Syrina™ 2.25, which utilises cutting edge drug delivery technology, brings the flexibility of being able to design a truly unique form factor to the market.”
Syrina™ 2.25 utilises the standard 2.25ml pre-filled syringe, based on Bespak’s proprietary VapourSoft™ technology and will also be available in a 1ml version.
The VapourSoft™ powerpack system helps overcome issues seen in spring-based auto-injectors. Based on proven valve technology, a small novel container of liquefied gas serves as a new power source. The propellant, when released, provides sufficient energy, in the form of a pressurised vapour, to power drug delivery and other functions. The consistent delivery performance across the Syrina™ product range gives researchers and biopharmaceutical companies the ability to use Syrina™ with VapourSoft™ at a very early stage of development. Several variations of the devices are available for clinical trials with a range of industrial designs being considered for the body of the auto-injectors to best suit patient needs. The Syrina™ auto injector with VapourSoft™ platform is proven to accommodate multiple primary containers, as well as high viscosity and high volume injections.
About Bespak:
Bespak is a global market leader in the design, development and manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market. http://www.bespak.com.
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 3 735 8168 or e-mail; t.jervis@defacto.com.
Steven Kaufman, Bespak’s Global Business Development Lead, commented: “India’s biopharmaceutical sector is on the look-out for highly innovative drug and delivery device solutions that provide a competitive edge for their products. Consequently, we are seeking to use this event to maintain our close relationships with our customers, whilst demonstrating how we can best service their needs with advanced drug delivery device technology that further increases value by helping to differentiate their generic, biobetter and biosimilar drugs.”
He continued: “For example, we will be demonstrating how our latest addition to the Syrina™ product range, the Syrina™ 2.25, which utilises cutting edge drug delivery technology, brings the flexibility of being able to design a truly unique form factor to the market.”
Syrina™ 2.25 utilises the standard 2.25ml pre-filled syringe, based on Bespak’s proprietary VapourSoft™ technology and will also be available in a 1ml version.
The VapourSoft™ powerpack system helps overcome issues seen in spring-based auto-injectors. Based on proven valve technology, a small novel container of liquefied gas serves as a new power source. The propellant, when released, provides sufficient energy, in the form of a pressurised vapour, to power drug delivery and other functions. The consistent delivery performance across the Syrina™ product range gives researchers and biopharmaceutical companies the ability to use Syrina™ with VapourSoft™ at a very early stage of development. Several variations of the devices are available for clinical trials with a range of industrial designs being considered for the body of the auto-injectors to best suit patient needs. The Syrina™ auto injector with VapourSoft™ platform is proven to accommodate multiple primary containers, as well as high viscosity and high volume injections.
About Bespak:
Bespak is a global market leader in the design, development and manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market. http://www.bespak.com.
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 3 735 8168 or e-mail; t.jervis@defacto.com.